We are pleased to announce our strategic partnership with Wellesta for commercializing VECanDx™ ELISA test for early detection of bladder cancer.

Wellesta and BioCheetah have signed an agreement whereby Wellesta will be commercializing BioCheetah’s unique, patented and biomarker-based test kit, VECanDx™ ELISA test for early detection of bladder cancer. This product will be sold, marketed and distributed in ASEAN, Indian sub-continent, MENA, EU and LATAM.

BioCheetah’s VECanDx™ ELISA test is a non-invasive test used to detect bladder cancer in hematuria patients and high-risk individuals. This Enzyme-linked immunosorbent assay (ELISA) test is a standard procedure which are well-established in hospitals and laboratories to detect five specific patented protein biomarkers that are present in bladder cancer.

Bladder cancer incidence rate is growing every year and further worsening with other lifestyle habits and issues such as obesity, diabetes and smoking. Thus, this strategic move will help the patients with early-stage screening of bladder cancer, support the medical community by bringing efficient, robust and good quality screening tool in the market.

While talking about this partnership, Dr. Kian-Chung Lee, CEO and co-Founder of BioCheetah said, “We are happy to join hands with Wellesta to commercialise VECanDx™ ELISA test kit to provide high sensitivity and specificity for diagnosis and monitoring of bladder cancer through urine-based biomarkers panel. With a fast-growing company like Wellesta, we are definite to achieve our goal to provide access to early cancer detection technology to many larger territories.”

The Chairman and MD of Wellesta, Mr. Milan Paleja added, “BioCheetah’s bladder cancer detection kit offers affordable and accurate detection of bladder cancer for early treatment. This aligns with Wellesta’s objective to provide high quality, right priced innovative products for better patient outcomes. We would be commercializing this product country by country, in ASEAN, Indian sub-continent, MENA, EU and LATAM countries.”

BioCheetah also has products in pipeline which are under development and will be available for commercialization once developed.

About Wellesta:

Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in Southeast Asia & India as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

Wellesta Holdings operate in a spectrum of business verticals under partner brands and own brands including pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta works as an extended arm for our principals through win-win partnership and provides superior quality products and services at the right price, by working at full compliance and transparency in our business approach.

For further information, visit: http://www.wellesta.com and our LinkedIn page.

About BioCheetah:

BioCheetah Private Limited, is a Singapore-based start-up diagnostics company set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. We are a company using patented bladder cancer biomarkers and detection antibodies for development of in-vitro diagnostic ELISA and Point-of-care test (POCT) kits for urological cancers. BioCheetah currently has an ISO13485 pilot production facility in Singapore for the purpose of development and small-scale manufacturing of its diagnostic products. Our goal is to manufacture diagnostics kits to allow healthcare providers to triage patients using our products with fast turnaround, exceptional quality, and competitive pricing via novel biomarkers for the diagnosis and recurrence monitoring of bladder cancer and other urological cancers.

The company is currently running clinical trials worldwide with hospitals in Singapore, China and France and anticipate the completion of these trials in Quarter 4 2023, before applying for Singapore’s Health Sciences Authority and US FDA 510(k) product registry in Q1 2024.

BioCheetah’s website is www.biocheetah.com